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ABSTRACT
The Global Cancer Genomics Consortium (GCGC) is a cohesive network of
oncologists, cancer biologists and structural and genomic experts residing in six
institutions from Lisbon, United Kingdom, Japan, India, and United States. The team
is using its combined resources and infrastructures to address carefully selected,
shared, burning questions in cancer medicine. The Third Annual Symposium was
organized by the Institute of Molecular Medicine, Lisbon Medical School, Lisbon,
Portugal, from September 18 to 20, 2013. To highlight the benefits and limitations of
recent advances in cancer genomics, the meeting focused on how to better translate
our gains in oncogenomics to cancer patients while engaging our younger colleagues
in cancer medicine at-large. Over two hundreds participants actively discussed some
of the most recent advances in the areas cancer genomics, transcriptomics and
cancer system biology and how to best apply such knowledge to cancer therapeutics,
biomarkers discovery and drug development, and an essential role played by biobanking throughout the process. In brief, the GCGC symposium provided a platform
for students and translational cancer researchers to share their excitement and
worries as we are beginning to translate the gains in oncogenomics to a better cancer
patient treatment.

INTRODUCTION

initiative connecting members and their institutions from
Lisbon, United Kingdom, Japan, India and United States.
The GCGC network holds an annual meeting to discuss
and debate the most pressing issues in cancer research
and treatment, share their recent findings, exchange
research ideas, and train students, young scientist and
faculty members, in cutting-edge cancer genomics and
need of cancer patients. The Third Annual Symposium
was held at the Institute of Molecular Medicine, Lisbon

The Global Cancer Genomics Consortium
(GCGC) functions as a cohesive interface that aligns a
multidisciplinary team of cancer and structural biologists,
computational genomics experts, and oncologists to
address shared global cancer research challenges through
the application of high-throughput technologies using
resources from its network. The GCGC is a dynamic
www.impactjournals.com/Genes & Cancer
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Medical School, Lisbon, Portugal, from September 18 to
20, 2013, attracted 215 participants, and counted with 25
invited platform speakers and 29 poster presenters. Once
again, the GCGC Symposium brought together a highly
motivated group of clinical and research cancer specialists
and scientists, students and young researchers to share
their latest results and ideas for translating the benefits of
post-genomic advances in cancer medicine to improve the
life of cancer patients.

researchers need to be inclusive of a broader patient
base and tumor acquisition supported by an improved
bioinformatics for its eventual utility by all. Dr. Hudis
concluded his lecture by sharing the ASCO’s CANCER
LINQ project.
Dr. Eric Winer from the Dana-Farber Cancer
Institute focused on the contribution of genomics to the
molecular diagnosis of breast cancer patients and their
treatments. Until this point, the convergence of clinical
and genomic data led to four families of breast cancer:
the “basal-like”, the HER-2+; the Luminal B (estrogen
positive with high proliferative index) and the Luminal
A (estrogen positive with low proliferative index). Up
to this moment, this sub-classification can be used to
assess prognosis and to determine appropriate treatment
toward a more personalized therapy. It has been also
useful to drive research in order to assess changes in
treatment response to each one of the sub-types, as well
as to characterize better mechanisms of resistance to the
available treatments and discover new “druggable” targets.
Single gene changes responsible for somatic alterations
or germ line mutations are also under the most desirable
new findings in genomic research. For example, HER-2
and BRCA genes alterations are the most relevant gene
alterations with clinical impact. Mutations in the PI-3K
pathway are among the most common mutations in breast
cancer, particularly in ER positive and in HER2 positive
tumors. However, despite of the fact that a large number
of new drugs are in pipeline, only a handful options are
advancing to the clinical scenario.
Dr. Rakesh Kumar from the George Washington
University focused on how RNA sequencing efforts could
provide new insights into breast cancer transcriptome.
The McCormick Genomic and Proteomic Center (MGPC)
team has recently completed an extensive comparative
analyses of triple-negative breast, estrogen receptor
positive, and HER2 positive breast cancers and presented
a comprehensive digital transcriptome [1]. This work led
to identification of novel and unannotated transcripts,
breast cancer sub-type specific transcriptomic adaptations,
and clues about new set of modulators of breast cancer.
Using in-house pipelines, the team also delineated splicing
signatures and differentially spliced genes in human
transcriptome. In general, distinct patterns of primary
transcripts and promoter switching in breast cancer were
identified and these molecular changes might contribute
to the noted heterogeneity of breast cancer transcriptome.
Using the same RNA-sequencing primary datasets,
algorithms were also developed to recognize the genetic
variance of breast cancer in the context of its allelic
preferential expression, and splicing signatures. Together
with Drs. Badwe and Gupta from the Tata Memorial
Center Mumbai, Prof. Kumar’s team unlocked the
transcriptomic insights of breast tumors from a subset of
breast cancer patients were treated with a single injection
of progesterone prior to the surgery [2]. Dr. Kumar also

Focus on the Clinical Relevance of Oncogenomics
The third meeting was focused on the integration
of the knowledge and translational strategies in the
post–genomic era toward its clinical applicability. The
symposium was opened by Prof. Luis Costa from the
Institute of Molecular Medicine and Hospital de Santa
Maria, and the introductory welcome remarks by Prof.
Lobo Antunes from the same institution. Profs. Costa
and Lobo Antunes shared the message of the Annual
GCGC Symposium, emphasizing the importance of
assessing the clinical relevance of knowledge that is
being generated in post-genome-sequencing era with
an overall goal to develop effective diagnostic and
therapeutic outcomes for cancer patients. The meeting
was organized into eight platform sessions and one
poster session, and included two keynote lectures. The
symposium focused on eight major scientific and clinical
themes: 1) breast cancer genomics and transcriptomics:
where do we stand?; 2) current application of genomics
in cancer therapy; 3) genomic approaches to facilitate
biomarkers discovery and drug development; 4) genomics
in clinics: biobanking; 5) innovative clinical trial designs
in the era of cancer genomics; 6) application of cancer
genomics research; 7) cancer system biology: cancer
transcriptome, proteome and metabolome; and 8) how to
integrate microenvironment and metabolomics with cancer
genomics. The meeting concluded with a panel discussion
about the future and next steps of GCGC research projects.

Breast Cancer Genomics and Transcriptomics:
Where do We Stand?
The theme was introduced by the opening keynote
lecture by Dr. Clifford Hudis from the Memorial SloanKettering Cancer Center, and President of American
Society of Clinical Oncology (ASCO). Dr. Hudis
focused on the current role and future prospects of
genomics and highlighted the need to broaden our
understanding of genomic changes including complex
and interacting alterations, functional alterations without
conventional structural changes in solid tumors. He also
stressed the possibility of considering even alternative
or complimentary explanations for the growth of some
malignancies. Dr. Hudis reinforced that clinicians and
www.impactjournals.com/Genes & Cancer
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presented results from on-going collaboration with the
Institute of Molecular Medicine in Lisbon, where the team
is revealing the transcriptome of bilateral breast cancer
with different tumor types.
Dr. Caterina Marchió from the Turim University
addressed the gap between genomics and molecular
pathology in the management of patients with breast
cancer. Dr. Marchió highlighted new promises and
challenges involved in on-going rapid integration of
massive parallel next generation sequencing into clinical
arena. In order to fill in the gap between genomics and
modern pathology (which appears still conspicuous),
tests will definitely play a role in diagnostic breast cancer
pathology, it will be important for pathologists to be
ready to integrate such developments into diagnostic
breast cancer pathology while ensuring the best clinical
management of breast cancer patients.
To conclude this session, Dr. Nikhil Wagle
from the Dana-Farber Cancer Institute discussed
the use of systematic genomic profiling approaches
– including hotspot genotyping, targeted massively
parallel sequencing, and whole exome sequencing –
to better understand the molecular determinants of
tumorigenesis, characterize mechanisms of therapeutic
response and resistance, and identify actionable genomic
alterations to aid with clinical decision-making. These
approaches include hotspot genotyping, targeted massively
parallel sequencing and whole exome sequencing. Dr.
Wagle also highlighted the need to test the “genomicsdriven” cancer medicine hypothesis through novel
clinical trial design and centralized shared databases [3,4].
Dr. Wagle presented the initial results from the CanSeq
initiative, collaboration between the Broad Institute,
Dana-Farber, and Brigham and Women’s Hospital, on the
prospective whole-exome sequencing for patients with for
the benefits of clinically actionable results [5]. To conclude
Dr. Wagle reinforced the notion that genomic profiling
technologies are changing the way we will practice
oncology by identifying new therapeutic opportunities as
we can now identify common and rare genomic alterations
(“the long tail”) in patients with cancer that might predict
responses to novel targeted therapies. Although efforts are
underway to implement tumor genomic profiling platforms
in the clinical arena, the interpretation of genomic
alterations and the incorporation of such data into clinical
care continue to be challenging. The “genomics-driven”
cancer medicine hypothesis is beginning to be tested – we
need clinical trials and shared databases to best answer
the question.

proteins implicated in the regulation of splicing machinery
and suggested such molecules as potential targets for
anticancer treatment. Dr. Carmo-Fonseca also shared some
innovative data about the identification of splicing factors
that are mis-regulated in cancers. Recurrent mutations
in genes encoding essential components of the splicing
machinery such as U2AF1 and SF3B1 are related to
cancer. Dr. Carmo-Fonseca focused on the potential role
of spliceostatin in blocking the formation of a catalytic
spliceosome and raised the possibility of using such
approaches in cancer therapeutics [6].
This was followed by Dr. Sudeep Gupta from the
Tata Memorial Hospital presented a genetic/genomic
perspective on gynecological cancers. Dr. Gupta focused
on focus on ovarian cancer with a particular emphasis
on high grade serous subtype. Dr. Gupta presented
recent studies dissecting the molecular heterogeneity
of ovarian cancer [7], and contributing to the new
classification of ovarian cancer into the so called Type
1 and Type 2 tumors [8]. From the genomic perspective,
he highlighted the TCGA initiative and outlined the
progress in our understanding of differences between
different types of ovarian cancer in clinical presentation,
genetic predisposition, hallmark molecular abnormalities,
response to treatment and outcome.
Dr. Raquel Seruca from IPATIMUP (Institute of
Molecular Pathology and Immunology at the University
of Porto) review the severe effects caused by CDH1
pathogenic variants and discuss how these novel findings
can be applied for the development of novel screening
tools and the development of therapeutic strategies to treat
patients harbouring carcinomas associated with the loss
of E-cadherin. CDH1 germ line mutations and somatic
alterations cause hereditary diffuse gastric cancer and have
been extensively studied by Dr. Seruca and colleagues [9].

Genomic Approaches to Facilitate Biomarkers
Discovery and Drug Development
The relevance of genomics in biomarkers and drug
development was addressed in the next presentations.
Dr. Masakazu Toi from the Kyoto University School
of Medicine focused on how the development of new
predictive biomarkers could help to maximize the
treatment efficacy and mimic the burdens toxicity and cost
of anti-HER2 therapy in breast cancer. The list of validated
markers to predict treatment response continues to be
limited considering the wealth of genomic information
available. The search for markers which could effectively
predict of response to MTOR inhibitors is on. This area
of development is focused on the role of S6 kinase,
PTEN status and PI3K mutation to predict the response
to mTOR inhibitors. Dr. Toi underlined the importance of
inter-observer concordance for IHC tests, such as the Ki67 proliferative index in breast cancer as the reliability of

Application of Genomics in Cancer Therapy
The meeting brought together three leading experts
to discuss emerging applications of genomic-driven
findings to the cancer therapy. Dr. Carmo-Fonseca
attempted to link cancer with altered expression of
www.impactjournals.com/Genes & Cancer

3

Genes & Cancer

Genomics in Clinics -Bio-banking

Ki67 test in grade 2 tumors is not very clear at the moment
as compared to high-expressing grade 3 tumors.
Dr. João Nuno Moreira from the Center for
Neuroscience and Cell Biology of University of Coimbra
presented a new rationale for the to development of
therapies -targeting tumor microenvironment on the basis
of characterized mechanisms while improving access
to intracellular sites of actions. Dr. Moreira stressed the
potential of ligand-mediated targeted delivery as well as
nanotechnologies-based approaches in the treatment of
solid tumors such as breast cancer [10]. The systemic
delivery of siRNA was also addressed [11].
Dr. Radhakrishnan Pillai from the Rajiv Gandhi
Center of Biotechnology addressed the significance of
cancer stem cell hypothesis, which puts forth that cancer
cells have a hierarchical developmental structure in which
only a fraction of cells termed cancer stem cells (CSCs)
can proliferate indefinitely to form tumors. Dr. Pillai
presented preliminary evidences for rare escape of tumor
cells from drug induced cell death, after an intermediate
stay in a non-cycling senescent stage followed by unstable
multiplication. Dr. Pillai’s data suggested indicated that
rare cancer cells escape from drug induced caspase
activation by entering into a high ROS quiescence state
followed by re-activation of anti-oxidant systems to
help them to stabilize several transcription factors (such
as NRF2 & OCT 4) and stem cell markers. Long term
chemical hypoxia treatment could lead to expansion of
drug efflux population and stabilization of HIF1-alpha
while cells escaping hypoxia tend to be more invasive. Dr.
Pillai concluded by presenting some new data on the use
of this knowledge to design better screening methods for
anti-cancer drug discovery.
This session was ended by Dr. Luís Costa’s
presentation, emphasizing the need of biology-driven
clinical research to drug development wherein both
the target and the disease model are equally important.
Prof. Costa stressed that the success of biology-driven
trials will be dependent on the discovery of reliable
biomarkers. Dr. Costa believes that one of the great
challenges to accelerate drug development in cancer care
is the promotion of transversal-biology at the clinical and
scientific level. Important information driven from biology
and from clinical research observation can be transferred
across different tumor types that share common drivenevents at different stages. Tumor-host bio-banking
designed to address these hypothesis is crucial to support
a transversal-translational-research. Dr. Costa also pointed
how the GCGC mission to foster the creation of these
multidisciplinary research teams an earlier intervention
at the pre-graduation level would be desirable to develop
both clinicians and scientists with transferable language
and tasks.

www.impactjournals.com/Genes & Cancer

The theme was introduced by the opening keynote
lecture by Dr. Carlos Caldas from the Cancer Research
UK. Dr. Caldas made an exciting presentation highlighting
the molecular characterization of 2,000 breast cancers to
illustrate stratification of breast cancer into 10 subtypes
with distinct biology and clinical outcomes. Genomewide copy number profiling of 997 tumors has revealed
additional heterogeneity within the intrinsic sub-types
of breast cancer. Joint clustering of copy number and
expression data lead to a new molecular taxonomy of
breast cancer. Such an approach improved prediction
of outcome in ER+/HER2- cases and exhibited distinct
prevalence and pattern of metastasis and sub-groups [1214].
The remainder of the session focused on the
strict connection between research-driven tumor biobanking and the translational research outcomes. Dr.
Fátima Carneiro from IPATIMUP and Hospital de
São João emphasized a crucial role that pathologists in
translational research by the establishment of a bridge
between clinicians and basic researchers. Dr. Carneiro
demonstrated why tumor banks are a vital resource for
cancer research, using the example if the Portuguese
National Network of Tumor Biobanks.
Dr. Sandra Casimiro from Instituto de Medicina
Molecular focused on her experience in colorectal cancer,
bone metastases and breast cancer bio-banking. Dr.
Casimiro presented a workflow for a successful strategy
in tumor bio-banking, and demonstrated the different
potential of project-driven tumor bio-banking versus the
broad prospective collection of tumor specimens by a
dedicated structure like Biobank IMM [15].
Next, Dr. Cláudia Faria from the Labatt Brain Tumor
Research Center and Hospital de Santa Maria explained
bio-banking primary brain tumors and brain metastases.
She also summarized the mission of the Medulloblastoma
Advanced Genomics International Consortium (MAGIC)
and collaborative bio-banking activities at IMM involving
tumor tissue, blood and plasma samples as well primary
stem cell culture.

Innovative Clinical Trial Designs in the Era of
Cancer Genomics
This session debated the impact of cancer genomics
in a “new” design of clinical trials. Dr. Nancy Lin from
Dana-Farber Cancer Institute pointed the challenge in
the screening and recruitment of patients in this new era
of molecular stratification and addressed the question
whether we are prepared or not to test new discoveries
in cancer genomics. Testing new discoveries can be
challenging for several reasons: testing is complex,
requires novel methods only available in academic or
4
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other specialized laboratories, asks for reproducibility, the
object of testing is not routine; requires research consent
and retrieval of tissue; potentially more tissue is required,
there is higher likelihood of failure to obtain results; and
the risk of “using up” tissue; frequently the turnaround
takes time like weeks to months. Most important, there is
only preclinical evidence and limited phase I data before
initiation of proof-of-concept studies [16]. Finally, Dr. Lin
suggested that some (if not most) of genomics data will
be valuable in identifying resistance mechanisms and new
targets that could be applied more broadly rather than in
directing the care of individual patients.
Dr. Alberto Bardelli from the University of Turim
discussed on the molecular alterations in KRAS, NRAS,
BRAF and MET and their association with the onset
of acquired resistance to anti-EGFR blockade in colon
cancer. Dr. Bardelli presented an optimized diagnostic
platform to identify resistance-associated genetic
alterations in the blood of patients (liquid biopsy) months
before radiographic documentation of disease progression,
providing the rationale for delaying or reversing resistance
to anti EGFR therapies in colon cancer and such a model
could be used for designing molecularly driven- clinical
trials [17].
Dr. Ian Krop from Dana-Farber Cancer Institute
approached the question whether the actual design of
clinical trials is prepared to test the new discoveries of
cancer genomics. The development of validated markers
is crucial in this setting. The design of phase II biomarkerdriven trials was discussed and sample size considerations
were presented in the enrichment design and randomized
block design of clinical studies. Most studies performed
the biomarker analysis using primary tissues rather than
therapy refractory samples. Dr. Krop suggested that the
study of circulating tumor cells and circulating DNA can
also provide relevant information about the progression of
disease. The question of therapeutic resistance continues to
be one of the most understudied areas with only a handful
of validated mechanisms. Therefore, there is a strong need
to evaluate metastatic tumor samples in refractory patients

talked about how structural information has facilitated
chemical biology programs that aim to develop selective
inhibitors that can be used as tool molecules to study the
role of kinases in RNA splicing and structural comparison
of the generated crystal structures revealed structural
features that can be utilized for the development of highly
specific inhibitors. Dr. Knapp research on the development
of selective kinase inhibitors has focused on Cdc2-like
kinases (CLKs), which are splicing regulators and found
to be deregulated in many cancers. The effects of specific
inhibition of CLK1 on TS splicing in endothelial cells,
the effect of SRPK2 on VEGF splicing, and the effect of
DIRK inhibition, were presented as relevant examples of
kinase inhibitors potential.
On the last presentation of this session Dr. Sérgio
Dias from Instituto de Medicina Molecular presented
recent data showing the metabolic alterations in
microenvironment gives instructive cues that regulate/
modulate the metastatic potential of cancer cells, using
models of hematological and solid cancers. Dr. Dias
focused on how a high fat systemic environment affects
cancer behavior. He shared recent data showing that mice
on hypercholesterolemic diet present bigger breast tumors,
with higher proliferation, migration, and mesenchymal
traits, and lower adhesion, more prone to progress into
the central nervous system [18]. Dr. Dias has previously
shown high cholesterol perturbs the bone marrow
microenvironment [19]. He also presented data showing
increased leukemia burden and spread on high cholesterol
mice, with higher trans-endothelial migration, probably
due to CX3CR1 induction [20].

Need to Integrate Microenvironment
Metabolomics with Cancer Genomics

In the final session of this meeting, speakers
highlighted the importance of tissue microenvironment on
the comprehension and analysis of cancer genomics data.
Dr. Sandra Casimiro from Instituto de Medicina Molecular
focused on the ‘vicious cycle’ of bone metastases and
on the need to identify and dissect the mechanisms and
events involved in bone colonization within different subtypes of breast cancer. This can lead to new prognostic
and predictive markers, and to new potential therapeutic
molecules specifically targeting the tumor compartment of
bone metastases. Dr. Casimiro showed how pre-clinical
research with cancer cell lines and animal models is being
translated into clinical models, by sharing gene expression
signatures of metastases [15], and showed evidence that
targeting RANKL-RANK pathway may also affect the
tumor compartment of bone metastases [21].
Dr. Fátima Baltazar from the University of
Minho talked about the expression of monocarboxylate
transporters (MCTs) and the MCT1/4 chaperone CD147,
in human cancers [22]. MCT isoforms 1 and 4 mediate

Cancer System Biology: Cancer Transcriptome,
Proteome and Metabolome
Dr. Anelia Horvath from George Washington
University shared latest GCGC data on characterization
of the genetic variance of 17 tumors representing the most
common breast cancer receptor subtypes: triple-negative
(TNBC), non-TBNC and HER2-positive breast cancer,
using whole transcriptome sequencing [1]. This study
illustrates the power of RNA-sequencing in revealing
the variation landscape of breast transcriptome and
exemplifies analytical strategies to explore regulatory
interactions among cancer relevant molecules.
Next Dr. Stefan Knap from the University of Oxford
www.impactjournals.com/Genes & Cancer
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the plasma membrane efflux of lactate coupled with a
proton, playing an important role in the maintenance
of the metabolic phenotype of tumours. The pattern of
MCT expression varies with cancer types and MCT
overexpression has important associations with tumor
aggressiveness. In general, MCT inhibition in glycolytic
tumour cells leads to a decrease in lactate production,
cell proliferation, migration and invasiveness [23].
Although MCT activity is essential for the maintenance
of the metabolic phenotype of tumours, however, MCTs
are differentially expressed among the solid tumours and
future strategies of MCT inhibition in cancer treatment
should take this fact into account.
Dr. Bruno Silva-Santos from Instituto de Medicina
Molecular focused on research on gamma-delta T
lymphocytes, which play key, non-redundant anti-tumor
roles in animal models of tumor development. Dr. Silva
Santos also spoke about stress-inducible determinants
of anti-tumor gamma-delta T cell responses and its
implications for manipulating lymphocyte lineage in
cancer immunotherapy. His work has identified markers
of susceptibility versus resistance to gamma-delta T
cell-mediated cytotoxicity. Expression and functional
studies also identified the chemokine CCL2 as a major
determinant of gamma-delta T cell infiltration into solid
tumors and counter-receptor CCR2 to infiltrate tumors in
vivo, where they inhibited tumor cell growth [24].
Finally, Dr. João Barata from Instituto de Medicina
Molecular shared new data on how IL-7 and IL-7R
constitute an important oncogenic axis in T-cell leukemia,
underpinning the relevance that both cell-autonomous
and cell extrinsic cues can have in promoting cancer.
Dr. Barata showed how IL-7 accelerates human T-ALL
expansion in vivo [25]; IL-7R mutational activation
promotes T-ALL [26]; forced wild type IL7R expression
appears to promote T-cell oncogenesis.

while asking meaningful translational cancer medicine
questions. The meeting participants also felt the need of
start better integrating cancer transcriptome with proteome
to promote targeted cancer therapeutics. Drs. Luis Costa
and Rakesh Kumar closed the meeting by announcing that
the next meeting will focus on Epigenome and Cancer
Medicine and the 4th GCGC meeting and will be held
at the Kyoto University Graduate School of Medicine,
Kyoto, Japan in 2014.
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